EGFR and non-small cell lung carcinoma: Prospective clinical trials have clearly demonstrated that EGFR TKIs are effective therapeutics that carry a 60–82% response rate[2], [5]–[7] and improve progression-free survival (PFS) with 7.7–13.3 months in NSCLC EGFR-mutant patients[2], [5]–[7].